Financial Performance - The company's operating revenue for Q1 2023 reached RMB 611,252,893.65, representing a year-on-year increase of 29.06%[3] - Net profit attributable to shareholders was RMB 81,177,581.15, reflecting a growth of 33.21% compared to the same period last year[3] - Basic and diluted earnings per share were both RMB 0.47, marking a 34.29% increase from the previous year[3] - Total operating revenue for Q1 2023 reached RMB 611.25 million, a 29.1% increase from RMB 473.62 million in Q1 2022[18] - Net profit for Q1 2023 was RMB 84.95 million, up 33.9% compared to RMB 63.48 million in Q1 2022[19] - The company reported a total profit of RMB 112.10 million for Q1 2023, compared to RMB 69.81 million in Q1 2022, marking a 60.2% increase[18] Cash Flow - The net cash flow from operating activities increased significantly to RMB 79,930,962.49, a rise of 1,687.78% year-on-year[3] - Cash flow from operating activities for Q1 2023 was RMB 79.93 million, significantly higher than RMB 4.47 million in Q1 2022[22] - Cash flow from investing activities showed a net inflow of RMB 156.18 million in Q1 2023, compared to a net outflow of RMB 174.41 million in Q1 2022[21] - Cash flow from financing activities resulted in a net outflow of RMB 20.94 million in Q1 2023, an improvement from a net outflow of RMB 121.58 million in Q1 2022[23] Research and Development - Research and development expenses totaled RMB 53,624,174.05, accounting for 8.77% of operating revenue, a decrease of 0.84 percentage points year-on-year[3] - Research and development expenses increased to RMB 53.62 million in Q1 2023, representing a 17.8% rise from RMB 45.52 million in Q1 2022[18] Assets and Liabilities - Total assets at the end of the reporting period were RMB 6,984,036,145.39, up 1.33% from the end of the previous year[3] - Current assets totaled RMB 3,660,348,521.72, up from RMB 3,532,115,166.92 in the previous period, reflecting a growth of approximately 3.63%[14] - Cash and cash equivalents were RMB 2,602,235,451.20, compared to RMB 2,544,591,061.46 at the end of 2022, indicating an increase of about 2.56%[14] - Total liabilities reached RMB 1,087,042,005.92, up from RMB 990,013,737.98, marking an increase of around 9.83%[16] - Long-term borrowings rose significantly to RMB 137,254,152.36 from RMB 43,979,665.36, indicating a substantial increase[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,369[6] - The total number of shares held by the top ten shareholders accounted for 81.53% of the total shares, indicating a high concentration of ownership[10] Market and Product Development - The increase in operating revenue was driven by the recovery of the domestic medical beauty industry and the strong market acceptance of the third-generation hyaluronic acid product "Haimai" [5] - Sales revenue from artificial lenses also saw significant growth due to an increase in cataract surgeries nationwide[5] - The company has been actively promoting its orthokeratology lens products, contributing to revenue growth in that segment[5] - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[12]
昊海生物科技(06826) - 2023 Q1 - 季度业绩